stars 1 stars 2 stars 3

Exactmer owns the Nanostar Sieving technology platform. This employs iterative, liquid-phase chemistry coupled to membrane purification, to create polymers of outstanding purity. Exactmer is currently advancing the production of oligonucleotides at scale, bringing these advanced therapeutics to all patients in need. Nanostar Sieving can also produce unimolecular polyethylene glycols (PEGs), including a disruptive new suite of multi-functional 'PEGabets', with handles for conjugation along the polymer backbone; ideal linkers molecules for Antibody Drug Conjugates.

Exactmer Questions

Cristina Bertulli is the Vice President of Business of Exactmer.

15 people are employed at Exactmer.

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users